Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds

Executive Summary

Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased

You may also be interested in...



Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments

BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24

Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments

BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24

FDA’s Sentinel Safety Surveillance Could Ease Phase IV Study Burden

FDA recognizes its Sentinel post-market safety surveillance project could help answer some questions that typically would be explored in Phase IV studies

Related Content

UsernamePublicRestriction

Register

PS049565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel